With a total revenue of Rs 1,180 crore in FY 2009-10, Biocon is back to the number one position in the BioSpectrum-ABLE Top 20 Survey 2010. after a gap of three years. Including its German subsidiary, Axicorp, the PAT of the company stood at Rs 293 crore with a year-on-year growth of 215 percent. The company also increased its licensing revenue from Rs 11 crore to Rs 51 crore.

Biocon's insulin business grew by 11 percent. In FY 2009-10, Biocon entered several new markets like Brazil and Chile. It also secured registration approvals in five countries during this year. The statin business of the company registered a year-on-year growth of 26 percent despite pricing pressures owing to enhanced capacity enabled by improved productivity. Simvastatin remained as the largest revenue incurring product by sales but Atorvastatin and Rosuvastatin are expected to boost the revenue in the coming years.

Axicorp posted 93 percent growth. The growth primarily came from more efficient sourcing of products for its business, restructuring of its sales force, and winning AOK, BKK and DKK tenders for several generics.

Biocon has acquired a new API facility in Hyderabad and is expanding its monoclonal antibody facility of its subsidiary, Biocon Biopharmaceuticals, which has recently been wholly-acquired from its Cuban partner. Its oncology segment posted 59 percent growth with brands like Abraxane and BioMAb EGFR as key contributers. The company plans to expand its auto-immune portfolio into dermatology and rheumatoid arthritis by launching the immunotherapy division this year.

Kiran Mazumdar-Shaw, CMD of Biocon, said, “We are confident of sustaining growth momentum in the years ahead given our increasingly differentiated profile enhanced by key global partnerships. This offers us larger and lucrative opportunities in both emerging and developed markets.�

Considering R&D pipeline, the company has strengthened its partnership with Mylan for developing biosimilars for the global markets. Its novel pipeline has achieved significant milestones spearheaded by a key IND filing with the US FDA for its oral insulin program IN105.

Biocon's coveted T1h program, a novel anti-cd6 targeting monoclonal antibody, is also entering phase-III clinical trials for psoriasis. Additionally, its novel anti-CD20 molecule has completed preclinical studies and is expected to move into the clinical trial in India this year.

Among other developments, Biocon has signed a MoU with Malaysian Biotechnology Corporation to explore collaboration and potential investment in Malaysia's biotech industry. Biocon is in talks with Biotech Corp to manufacture biopharma products and formulations there.

Having a strong focus on R&D, the company in FY 2009-10, spent Rs 125 crore in research, a 45 percent rise over the previous year's investment of Rs 80 crore.